Supinoxin

DB19010InvestigationalSmall molecule

Supinoxin is under investigation in clinical trial NCT02003092 (RX-5902 Treatment of Subjects With Triple Negative Breast Cancer).

Chemical structure of Supinoxin
Formula / weight
C22H24FN5O4 · 441.463 g/mol (avg)
Also known as
1-(3,5-dimethoxyphenyl)-4-((6-fluoro-2-methoxyquinoxalin-3-yl)aminocarbonyl) piperazine · 1-piperazinecarboxamide, 4-(3,5-dimethoxyphenyl)-n-(7-fluoro-3-methoxy-2-quinoxalinyl)- · 4-(3,5-dimethoxyphenyl)-n-(7-fluoro-3-methoxy-quinoxalin-2-yl)piperazine-1-carboxamide · P-p68 inhibitor rx-5902
Code names
RX-5902

Resolves to

Compound
UNIIZU8OM8V5WFCAS888478-45-3ChEMBLCHEMBL1278118
Structure
InChIKeyKAKPGJJRYRYSTP-UHFFFAOYSA-NSMILESCOC1=CC(=CC(OC)=C1)N1CCN(CC1)C(=O)NC1=NC2=CC(F)=CC=C2N=C1OC
Targets
P17844DDX5

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Supinoxin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In